Luna Becomes the Fasting Growing PT Clinic Nationally, & Earns “Exceptional” Award from Medicare

Luna has become the fastest growing physical therapy (PT) clinic nationally[1] with 6,183% growth in visits during the four consecutive years since it was founded in 2018. This is higher than any reported growth during the same time frame from any PT clinic group.

Luna’s outpatient “rehab-at-home” model is shaking up healthcare and, to date, has treated over 25,000 patients. Delivering high quality in-person PT care to a patient’s home, Luna now operates across 45 markets in 25 states, with one of its thousands of licensed physical therapists visiting a patient’s home every 45 seconds.

Luna has earned the trust of countless patients, therapists, physicians, and partners, culminating in its recent designation as an “Exceptional” provider by the Medicare/CMS, the highest level of achievement possible in this category. This award by the Merit-based Incentive Payment System (MIPS) demonstrates Luna’s commitment to exceptional care and in particular enabling outcomes via significant pain and functional improvements for patients with lower back, knee, neck, and ankle conditions.

Health Systems and Orthopaedic Groups are Embracing Luna

Luna’s rapid growth is driven by partnerships with over 50 health systems and orthopaedic groups, including Emory Health, Intermountain Healthcare and UCLA Health, to address the $2.5 billion loss in annual revenue for health systems, given that 55% of PT patients referred to a health system clinic seek care outside the system.

“People will drive a long way to have surgery, but not a couple times a week to have rehab,” said Dr. Scott Boden, Director of the Emory Orthopaedics & Spine Center and Vice President for Business Innovation for Emory Healthcare. “Luna allows us to extend access to care to all patients across our metropolitan area, who otherwise might have been at a higher risk of failure because they didn’t have the right PT.”

Cost Effective Solution for At-Risk Providers

Luna recently demonstrated how its outpatient in-home PT saves an average of $3,000 per case for post-surgical rehab for bundled care cases, equating to Medicare savings of 55%-70% per case.

“Luna is the future of healthcare,” said Mike West, former CEO of Rothman Orthopaedic Institute. “90% of patients choose in-person delivery vs. a clinic when offered both choices. With Luna, health systems, surgeons, and orthopedic groups can ensure patients receive convenient, high quality care from their home.”

Unique Technology Platform and Network of Therapists

Using the Luna technology platform, physical therapists can optimize delivery of care via scheduling, matching, and routing – as well as incorporating charting, insurance claims, and documentation in a streamlined manner. Luna has introduced many innovations in its platform, including Auto-Charting®, Safety Shield®, Luna Protocols and Care Pathways, Luna Dashboards for physicians, and integrated Luna Exercises.

Unlike virtual-only or digital-only PT providers, Luna’s technology-first approach and network of exceptional and licensed therapists deliver the best of both worlds. This ensures physical therapists have access to specific protocols and care pathways to patients – and can track progress in real-time.

“Post-pandemic, consumers and providers are increasingly looking for ways to safely access and deliver rehab at home – and that’s what excites us about the future of healthcare,” says Palak Shah, Luna co-founder and head of clinical operations. “Our team of therapists and tech innovations makes us perfectly placed to deliver safe, high quality PT care in the patient’s home while providing critical relief for health systems.”

[1] Luna experienced growth of 6,183% in visits from 2018 to 2022, with >100% growth per annum for each of the four years.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy